Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients

NCT02041468 is registered in ClinicalTrials.gov with Jewish General Hospital as lead sponsor.

NCT NCT02041468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02041468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
Jewish General Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2014
Completion date
June 30, 2018
Enrollment
29 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic